Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

doi:10.1073/pnas.1703094114

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Proceedings of the National Academy of Sciences of the United States of America - 5 Sept 2017

Kurtz Stephen E, Eide Christopher A, Kaempf Andy, Khanna Vishesh, Savage Samantha L, Rofelty Angela, English Isabel, Ho Hibery, Pandya Ravi, Bolosky William J, Poon Hoifung, Deininger Michael W, Collins Robert, Swords Ronan T, Watts Justin, Pollyea Daniel A, Medeiros Bruno C, Traer Elie, Tognon Cristina E, Mori Motomi, Druker Brian J, Tyner Jeffrey W

Abstract excerpt

Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge. Large-scale sequencing efforts have uncovered a spectrum of mutations in many hematologic malignancies, including acute myeloid leukemia (AML), suggesting that combinations of agents will be required to treat these diseases effectively. Combinatorial approaches will also be critical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Hematologic Neoplasms

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Leukemia, Myeloid, Acute

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-bcl-2

Share to Receptors, Granulocyte-Macrophage Colony-Stimulating Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 28784769
DOI: 10.1073/pnas.1703094114
PMCID: PMC5594650

Genes

BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.PMID 28784769Read ↗

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read ↗

Identifying effective drug combinations for patients with acute myeloid leukemia.Semantic proximity Read ↗

Drug-perturbation-based stratification of blood cancerSemantic proximity Read ↗

Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependenciesSemantic proximity Read ↗

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatmentsSemantic proximity Read ↗

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity Read ↗

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read ↗

Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionSemantic proximity Read ↗

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.Semantic proximity Read ↗

Drug Resistance in Hematological MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.